Actively Recruiting
Safety and Effects of Single-Dose ATI-1013 Antibody Infusion in Healthy Adult Smokers Aged 23 to 59
Led by Antidote Therapeutics, Inc · Updated on 2025-10-15
15
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial investigates ATI-1013, a drug being studied in healthy adult cigarette smokers to understand its safety, how long it stays in the body, whether it causes an immune response, and its effects on nicotine levels. The study compares ATI-1013 to a placebo to evaluate safety and how the drug interacts with nicotine. It is a first-in-human, phase 1 clinical trial conducted by Antidote Therapeutics, Inc. Participants receive one intravenous infusion of ATI-1013 at one of three escalating doses 0.2 g, 0.8 g, or 3.2 g or a placebo. The study uses a randomized, double-blind design with a 41 ratio favoring ATI-1013 in each dose group. The trial includes a screening period, a dosing day with at least 48 hours of in-clinic observation, and follow-up visits on Days 7, 21, 42, 56, and 84, plus telephone check-ins on Days 5, 14, 28, and 70. Participants keep a diary of their cigarette use and smoking habits. Researchers monitor adverse events, immune responses, and drug levels in the blood over 84 days. They also track nicotine-related physiological responses such as skin temperature, heart rate, blood pressure, and withdrawal symptoms, along with subjective effects of nicotine. Safety and drug behavior in the body are key outcomes throughout the study period.
CONDITIONS
Brief Title
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
Research Team
L
Leslie OToole
A
Arjen DeVos, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here